title: Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells.
abstract: Based on differential levels of membrane-associated folate binding protein (mFBP) expression, murine L1210 leukemia, human KB epidermoid carcinoma, and human IGROV1 ovarian carcinoma cells maintained under low (physiological) folate conditions (2 nM folinic acid) were used as model systems to investigate the potential role of mFBP in antifolate transport. In addition, L1210 parental cells were compared to a subline, L1210A, expressing high levels of mFBP and defective reduced folate carrier. Antifolates for which KB-derived mFBP has high affinity (5, 10-dideazatetrahydrofolic acid [DDATHF] and homo-DDATHF [0.24 and 0.78 respectively relative to folic acid]) and low affinity (methotrexate [0.002]) were chosen for this study. Protection against DDATHF/homo-DDATHF induced cytotoxicity was achieved preferentially by folic acid compared to folinic acid in IGROV1 and L1210A cells. In IGROV1 cells, cytotoxicity IC50s were increased 18- and 5.5-fold for DDATHF and homo-DDATHF respectively by 20 nM folic acid. Moreover, greater protection was observed in L1210A cells, where IC50s were increased 354- and 80-fold for these same compounds by 20 nM folic acid. Similar protection was not observed in KB cells, suggesting that KB mFBP was not functional in DDATHF transport. Although mFBP expression may be an important determinant in the cytotoxicity of antifolates for certain tumor cells, our data demonstrate a lack of correlation between levels of mFBP and function of mFBP for DDATHF transport in the models studied.
authors.affiliation: Division of Cancer Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Schultz
authors.forename: S L
authors.initials: SL
authors.lastname: Andis
authors.forename: K A
authors.initials: KA
authors.lastname: Shackelford
authors.forename: S B
authors.initials: SB
authors.lastname: Gates
authors.forename: M
authors.initials: M
authors.lastname: Ratnam
authors.forename: L G
authors.initials: LG
authors.lastname: Mendelsohn
authors.forename: C
authors.initials: C
authors.lastname: Shih
authors.forename: G B
authors.initials: GB
authors.lastname: Grindey
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents; D002352:Carrier Proteins / Q000502:physiology*; D004347:Drug Interactions; D004354:Drug Screening Assays, Antitumor; D005260:Female; D058973:Folate Receptors, GPI-Anchored; D005492:Folic Acid / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000378:metabolism* / Q000494:pharmacology*; D006801:Humans; D007624:KB Cells / Q000187:drug effects; D002955:Leucovorin / Q000494:pharmacology; D007939:Leukemia L1210 / Q000188:drug therapy; D008565:Membrane Proteins / Q000502:physiology*; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011956:Receptors, Cell Surface; D014407:Tumor Cells, Cultured / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D002352:Carrier Proteins; D058973:Folate Receptors, GPI-Anchored; D005493:Folic Acid Antagonists; D008565:Membrane Proteins; D011956:Receptors, Cell Surface; D005492:Folic Acid; D002955:Leucovorin